Can tranexamic acid stop a gastrointestinal bleed?

Tranexamic Acid for Gastrointestinal Bleeding: Current Evidence

Tranexamic acid should NOT be routinely used to stop gastrointestinal bleeding, as the highest quality evidence shows no mortality benefit and potential harm, particularly increased thromboembolic events and seizures.

Evidence from Guidelines

The most recent and authoritative guideline on this topic comes from the British Society of Gastroenterology (2019), which explicitly addresses tranexamic acid in GI bleeding 1:

• For lower GI bleeding: Tranexamic acid use should be confined to clinical trials only, pending results of the HALT-IT trial 1
• While tranexamic acid improves mortality in trauma settings, pooled analysis of upper GI bleeding trials showed a 40% mortality reduction that disappeared when limited to trials at low risk of bias 1
• The studies supporting tranexamic acid are considered historic and predate routine high-dose acid suppression and endoscopic therapy, making extrapolation to modern care uncertain 1
• Studies have been too small to adequately assess thromboembolic event risk 1

The European Heart Rhythm Association (2018) guideline mentions tranexamic acid only as an adjuvant consideration (1g IV, repeated every 6 hours if needed) in special situations with associated coagulopathy or thrombopathy, not as primary therapy 2

The EASL guidelines on cirrhosis (2022) provide critical negative evidence: A large randomized trial of 12,009 patients with acute upper GI bleeding (nearly 50% suspected variceal) showed no beneficial effect of tranexamic acid on death due to bleeding 3. Importantly, this trial demonstrated an almost 2-fold increase in venous thromboembolic events in the tranexamic acid group, with risk concentrated in patients with liver disease 3.

Trauma Guidelines Are Not Applicable

The European trauma guidelines (2013) strongly recommend tranexamic acid for trauma patients (Grade 1A), but this applies specifically to traumatic hemorrhage, not GI bleeding 4. The CRASH-2 trial that supports trauma use enrolled trauma patients, not GI bleeding patients 4.

Recent High-Quality Research Evidence

The most recent systematic review and meta-analysis (2025) including 2,061,231 participants provides nuanced findings 5:

• Upper GI bleeding: Tranexamic acid reduced mortality (RR 0.72,95% CI 0.59-0.87) and rebleeding rates 5
• Lower GI bleeding: Tranexamic acid was associated with significantly increased mortality (RR 1.67,95% CI 1.44-1.93) 5
• No significant increase in thrombotic events overall, though this remains controversial 5

Another 2025 meta-analysis of 7 RCTs (13,608 participants) found 6:

• Reduced rebleeding (OR 0.64,95% CI 0.45-0.91) and failure to control bleeding (OR 0.55,95% CI 0.45-0.91) 6
• No significant mortality reduction (OR 0.77,95% CI 0.56-1.07) 6
• Fixed-effect analysis suggested increased thromboembolic events (OR 1.28,95% CI 1.07-1.55) 6

A 2024 systematic review (14,338 patients) concluded 7:

• No significant mortality difference (RR 0.86,95% CI 0.74-1.00) 7
• Increased risk of seizures (RR 1.73,95% CI 1.03-2.93) in one large trial 7
• Authors explicitly recommend against using tranexamic acid in acute GI bleeding 7

Special Population: Cirrhosis

A 2024 RCT in 600 patients with advanced cirrhosis (Child-Pugh B or C) showed tranexamic acid reduced failure to control bleeding by day 5 (6.3% vs 13.3%, p=0.006), particularly from post-EVL sites 8. However, 5-day and 6-week mortality were similar between groups 8. This represents a narrow indication that requires further validation.

Critical Safety Concerns

FDA labeling for tranexamic acid lists gastrointestinal symptoms (nausea, vomiting, diarrhea) as potential overdosage effects 9. The drug is indicated only for hemophilia patients undergoing tooth extraction, not for GI bleeding 9.

Clinical Bottom Line

Do not use tranexamic acid routinely for GI bleeding because:

1. No mortality benefit demonstrated in modern, low-bias trials 1, 3, 6, 7
2. Increased thromboembolic risk, particularly venous thromboembolism 3, 6
3. Increased seizure risk in large trials 7
4. Harm in lower GI bleeding with increased mortality 5
5. Guidelines recommend against routine use outside clinical trials 1

The primary management of GI bleeding remains endoscopic hemostasis, appropriate resuscitation, and proton pump inhibitors for upper GI bleeding 10. Tranexamic acid should only be considered in highly selected research settings or possibly in advanced cirrhosis with post-EVL bleeding, where evidence is emerging but not yet definitive 8.